HROW
Price
$42.59
Change
-$0.39 (-0.91%)
Updated
Jan 28, 04:59 PM (EDT)
Capitalization
1.58B
55 days until earnings call
Intraday BUY SELL Signals
VTRS
Price
$12.96
Change
-$0.16 (-1.22%)
Updated
Jan 28, 04:59 PM (EDT)
Capitalization
15.11B
33 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HROW vs VTRS

Header iconHROW vs VTRS Comparison
Open Charts HROW vs VTRSBanner chart's image
Harrow
Price$42.59
Change-$0.39 (-0.91%)
Volume$9.2K
Capitalization1.58B
Viatris
Price$12.96
Change-$0.16 (-1.22%)
Volume$109.06K
Capitalization15.11B
HROW vs VTRS Comparison Chart in %
HROW
Daily Signal:
Gain/Loss:
VTRS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
HROW vs. VTRS commentary
Jan 29, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HROW is a Buy and VTRS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 29, 2026
Stock price -- (HROW: $42.98 vs. VTRS: $13.12)
Brand notoriety: HROW and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HROW: 85% vs. VTRS: 86%
Market capitalization -- HROW: $1.59B vs. VTRS: $15.11B
HROW [@Pharmaceuticals: Generic] is valued at $1.59B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $15.11B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $66.29B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HROW’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 3 green FA rating(s).

  • HROW’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 3 green, 2 red.
According to our system of comparison, both HROW and VTRS are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HROW’s TA Score shows that 4 TA indicator(s) are bullish while VTRS’s TA Score has 2 bullish TA indicator(s).

  • HROW’s TA Score: 4 bullish, 5 bearish.
  • VTRS’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, HROW is a better buy in the short-term than VTRS.

Price Growth

HROW (@Pharmaceuticals: Generic) experienced а -9.93% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +3.63% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.01%. For the same industry, the average monthly price growth was +3.83%, and the average quarterly price growth was +17.84%.

Reported Earning Dates

HROW is expected to report earnings on Mar 25, 2026.

VTRS is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.01% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($15.1B) has a higher market cap than HROW($1.58B). VTRS YTD gains are higher at: 5.382 vs. HROW (-12.286). HROW has higher annual earnings (EBITDA): 39.4M vs. VTRS (-598.9M). VTRS has more cash in the bank: 1.16B vs. HROW (74.3M). HROW has less debt than VTRS: HROW (252M) vs VTRS (14.7B). VTRS has higher revenues than HROW: VTRS (14.1B) vs HROW (250M).
HROWVTRSHROW / VTRS
Capitalization1.58B15.1B10%
EBITDA39.4M-598.9M-7%
Gain YTD-12.2865.382-228%
P/E RatioN/A236.20-
Revenue250M14.1B2%
Total Cash74.3M1.16B6%
Total Debt252M14.7B2%
FUNDAMENTALS RATINGS
HROW vs VTRS: Fundamental Ratings
HROW
VTRS
OUTLOOK RATING
1..100
5881
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
11
Undervalued
PROFIT vs RISK RATING
1..100
46100
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
4910
P/E GROWTH RATING
1..100
111
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (11) in the null industry is significantly better than the same rating for HROW (80) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew significantly faster than HROW’s over the last 12 months.

HROW's Profit vs Risk Rating (46) in the Pharmaceuticals Other industry is somewhat better than the same rating for VTRS (100) in the null industry. This means that HROW’s stock grew somewhat faster than VTRS’s over the last 12 months.

HROW's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as VTRS (96) in the null industry. This means that HROW’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's Price Growth Rating (10) in the null industry is somewhat better than the same rating for HROW (49) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew somewhat faster than HROW’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as HROW (11) in the Pharmaceuticals Other industry. This means that VTRS’s stock grew similarly to HROW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HROWVTRS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
53%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
62%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 14 days ago
84%
Bullish Trend 7 days ago
70%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
59%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
HROW
Daily Signal:
Gain/Loss:
VTRS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBRRX27.330.12
+0.44%
Neuberger M/C Intrinsic Val R3
MUXYX28.610.12
+0.42%
Victory S&P 500 Index Y
RETSX97.890.25
+0.26%
Russell Inv Tax-Managed US Large Cap S
PSMLX32.940.03
+0.09%
Principal SmallCap R6
OCSVX10.74-0.02
-0.19%
Optimum Small-Mid Cap Value C

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AMRX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
-1.94%
AMRX - HROW
34%
Loosely correlated
+1.92%
TKNO - HROW
34%
Loosely correlated
-0.63%
VTRS - HROW
32%
Poorly correlated
-0.38%
AMLX - HROW
31%
Poorly correlated
+3.06%
AQST - HROW
29%
Poorly correlated
+7.10%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with AMRX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
-0.38%
AMRX - VTRS
50%
Loosely correlated
+1.92%
ELAN - VTRS
48%
Loosely correlated
-0.24%
AMPH - VTRS
45%
Loosely correlated
-1.32%
ZTS - VTRS
38%
Loosely correlated
+0.84%
TEVA - VTRS
37%
Loosely correlated
+1.21%
More